24 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
17
Structure-based design of novel, urea-containing FKBP12 inhibitors.
Agouron Pharmaceuticals
4
Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease.
Agouron Pharmaceuticals
27
Characterization of mono- and diaminopyrimidine derivatives as novel, nonpeptide gonadotropin releasing hormone (GnRH) receptor antagonists.
Agouron Pharmaceuticals
24
The discovery of novel small molecule non-peptide gonadotropin releasing hormone (GnRH) receptor antagonists.
Agouron Pharmaceuticals
20
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 6. Structure-activity studies of orally bioavailable, 2-pyridone-containing peptidomimetics.
Agouron Pharmaceuticals
26
Substituted benzamide inhibitors of human rhinovirus 3C protease: structure-based design, synthesis, and biological evaluation.
Agouron Pharmaceuticals
11
Synthesis and biological activity of oxo-7H-benzo[e]perimidine-4-carboxylic acid derivatives as potent, nonpeptide corticotropin releasing factor (CRF) receptor antagonists.
Agouron Pharmaceuticals
12
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements.
Agouron Pharmaceuticals
12
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics.
Agouron Pharmaceuticals
1
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies.
Agouron Pharmaceuticals
18
Tripeptide aldehyde inhibitors of human rhinovirus 3C protease: design, synthesis, biological evaluation, and cocrystal structure solution of P1 glutamine isosteric replacements.
Agouron Pharmaceuticals
15
Protein structure-based design, synthesis, and biological evaluation of 5-thia-2,6-diamino-4(3H)-oxopyrimidines: potent inhibitors of glycinamide ribonucleotide transformylase with potent cell growth inhibition.
Agouron Pharmaceuticals
14
Structure-based design of substituted diphenyl sulfones and sulfoxides as lipophilic inhibitors of thymidylate synthase.
Agouron Pharmaceuticals
24
Design, synthesis, and evaluation of nonpeptidic inhibitors of human rhinovirus 3C protease.
Agouron Pharmaceuticals
24
Design of thymidylate synthase inhibitors using protein crystal structures: the synthesis and biological evaluation of a novel class of 5-substituted quinazolinones.
Agouron Pharmaceuticals
6
Calculation of relative differences in the binding free energies of HIV1 protease inhibitors: a thermodynamic cycle perturbation approach.
Agouron Pharmaceuticals
15
Synthesis and biological evaluation of novel 2,6-diaminobenz[cd]indole inhibitors of thymidylate synthase using the protein structure as a guide.
Agouron Pharmaceuticals
14
Design of enzyme inhibitors using iterative protein crystallographic analysis.
Agouron Pharmaceuticals
14
Design and synthesis of novel 6,7-imidazotetrahydroquinoline inhibitors of thymidylate synthase using iterative protein crystal structure analysis.
Agouron Pharmaceuticals
26
Kinase modulating compounds, compositions containing the same and use thereof
Centaurus Biopharma
2
Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
SRMLSC